

| | |
|---|---|
| Name | Sung-Eun Lee |
| Current Position & Affiliation | Professor/ Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea |
| Country | Republic of Korea |
| Major Field | Myeloproliferative neoplasms, Chronic myeloid leukemia, Hematopoietic stem cell transplantation |

Educational Background

| | |
|----------------------------|---|
| March 1997 – February 2003 | Bachelor's degree The Hanyang Univ. of Korea, Seoul, Korea |
| March 2009 – February 2013 | Ph.D. degree The Catholic Univ. of Korea, Seoul, Korea |

Professional Experience

| | |
|----------------------------|---|
| March 2003 – February 2004 | Internship The Hanyang Univ. of Korea, Seoul, Korea |
| March 2005 – February 2009 | Residency, Department of Internal Medicine, The Catholic Univ. of Korea, Seoul, Korea |
| March 2009 – February 2013 | Clinical Fellow, Catholic blood and Marrow Transplantation Center, The Catholic Univ. of Korea, Seoul, Korea |
| March 2013 – February 2016 | Clinical assistant professor, Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea |
| March 2016 – March 2018 | Assistant professor, Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea |
| March 2018 – November 2019 | Postdoctoral Fellow, MD Anderson cancer center |
| April 2018 – February 2023 | Associate professor, Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea |
| March 2023 – | Professor, Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea |

Other Experience and Professional Memberships

1. Korean Society of Hematology
2. Korean Society of Hematopoietic Stem Cell Transplantation
3. Korean Society of Internal Medicine
4. Korean Medical Association
5. Korean Society of Experimental Hematology
6. Working group on cardio-oncology
7. CML Working Party, Korean Society of Hematology
8. MPN Working Party, Korean Society of Hematology

Main Scientific Publications

RESEARCH PAPERS (Recent Published as fist/corresponding authors)

1. Yoon SY, Yoon SS, Yang DH, Lee GW, Sohn SK, Shin HJ, et al. Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study. Int J Cancer. 2025.



2. Lee JY, Yoon SS, Yang DH, Sohn SK, Yoon SY, Bang SM, et al. Efficacy and Safety of Ropoginterferon Alfa-2b in Low-Risk Polycythemia Vera. *Cancer Res Treat.* 2025.
3. Lee J, Lee SE, Kwag D, Park SS, Park S, Uhm J, et al. Outcomes of Haploidentical Stem Cell Transplantation in Upfront and Salvage Settings for Adult Patients with Severe Aplastic Anemia. *Transplant Cell Ther.* 2025.
4. Kim KY, Han K, Lee SE. Associations between Waist Circumference, Body Mass Index, HDL Cholesterol Level, and Risk of Chronic Myeloid Leukemia. *Cancer Epidemiol Biomarkers Prev.* 2025;34:1210-8.
5. Yoon SY, Lee SE. Treatment with ropoginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study. *Blood Res.* 2024;59:23.
6. Kim TY, Eom KS, Lee JY, Lee JM, Kim M, Lee SE. Genetic and immunologic features associated with thrombocytopenia progression and poor prognosis in patients with myelofibrosis. *Front Med (Lausanne).* 2024;11:1461421.
7. Jung SH, Lee SE, Yun S, Min DE, Shin Y, Chung YJ, et al. Different inflammatory, fibrotic, and immunologic signatures between pre-fibrotic and overt primary myelofibrosis. *Haematologica.* 2024.
8. Lee SE, Hong J, Bang SM, Park J, Choi CW, Bae SH, et al. Differences in Clinical Outcomes Between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients. *J Korean Med Sci.* 2024;39:e24.
9. Lee J-M, Ahn A, Min EJ, Lee S-E, Kim M, Kim Y. Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation. *Blood Cancer Journal.* 2023;13(1):97
10. Lee SE, Wang F, Grefe M, et al. Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. *Clin Cancer Res.* 2023;15(1):172-179.
11. Bang SY, Lee SE. A Case Report of Ropoginterferon Alfa-2b for Polycythemia Vera during Pregnancy. *Hematol Rep.* 2023;15(1):172-179.
12. Kim TY, Kwag D, Lee JH, et al. Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients. *Cancers (Basel).* 2022;14(18).
13. Lee SE. Disease modifying agents of myeloproliferative neoplasms: a review. *Blood Res.* 2021;56(S1):S26-S33.
14. Lee SE, Min GJ, Park SS, et al. Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study. *Biol Blood Marrow Transplant.* 2020;26(10):1906-1914.
15. Lee S-E, Wang F, Trujillo-Ocampo A, et al. Fidelity of peripheral blood for monitoring genomics and tumor immune-microenvironment in myelodysplastic syndromes. *eJHaem* 2020;1(2):552-557.
16. Lee SE, Hyun Kong J, Kim SH, et al. Change of right ventricular systolic pressure can indicate dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia. *Cancer Med.* 2021;10(5):1515-1524.
17. Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. *Expert Opin Drug Saf.* 2021;20(2):171-179.
18. Lee SE, Lim JY, Ryu DB, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. *Biol Blood Marrow Transplant* 2019; 25(10):1933-1943
19. Lee SE, Lim JY, Kim TW, et al. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. *J Immunother Cancer* 2019; 7(1):35-47.

